Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05316181 | CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)(KOV-HIPEC-02R) | active not recruiting | Phase 3 | 140 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in Oncology |
| 1 |
| Feb 5, 2026 |
| clinicaltrials |
| NCT04169997 | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer(FLAMES) | active not recruiting | Phase 3 | 404 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | active not recruiting | Phase 3 | 437 | Bristol-Myers SquibbINDUSTRY | 14 | Jan 21, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 | Jan 13, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT02051218 | Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks | active not recruiting | Phase 3 | 1,380 | Swiss Cancer InstituteOTHER | 3 | Dec 30, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.(SOLO-1) | active not recruiting | Phase 3 | 450 | AstraZenecaINDUSTRY | 15 | Dec 10, 2025 | clinicaltrials |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line(DOMENICA) | active not recruiting | Phase 3 | 260 | ARCAGY/ GINECO GROUPOTHER | 10 | Dec 4, 2025 | clinicaltrials |
| NCT04537156 | Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) | active not recruiting | Phase 3 | 9,327 | Xiamen UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04982237 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 3 | 445 | AkesoINDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT01223248 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | active not recruiting | Phase 3 | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Nov 4, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT02194842 | Phase III Radium 223 mCRPC-PEACE III(PEACE III) | active not recruiting | Phase 3 | 446 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 19, 2025 | clinicaltrials |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(COSMIC-313) | active not recruiting | Phase 3 | 855 | ExelixisINDUSTRY | 25 | Sep 10, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05336786 | Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount) | active not recruiting | Phase 3 | 70 | Thomas Jefferson UniversityOTHER | 2 | Sep 4, 2025 | clinicaltrials |
| NCT01436968 | Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer(PrTK03) | active not recruiting | Phase 3 | 711 | Candel Therapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT01952223 | A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse(PEACE2) | active not recruiting | Phase 3 | 761 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04181203 | Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy(CARLHA-2) | active not recruiting | Phase 3 | 490 | UNICANCEROTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05056402 | An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old | active not recruiting | Phase 3 | 1,382 | Xiamen UniversityOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | active not recruiting | Phase 3 | 11,000 | University College, LondonOTHER | 2 | Jun 10, 2025 | clinicaltrials |
| NCT05219318 | Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors(SPICI) | active not recruiting | Phase 3 | 22 | University Hospital, BordeauxOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04302454 | Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy(ADOPT) | active not recruiting | Phase 3 | 280 | University Medical Center GroningenOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04557501 | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer(PATRON) | active not recruiting | Phase 3 | 800 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT02951325 | Bladder Cancer Adjuvant Radiotherapy Trial(BART) | active not recruiting | Phase 3 | 153 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT00223145 | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone(PCS III) | active not recruiting | Phase 3 | 600 | Abdenour NabidOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT00223171 | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers(PCS IV) | active not recruiting | Phase 3 | 630 | Université de SherbrookeOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients(ALBAN) | active not recruiting | Phase 3 | 517 | UNICANCEROTHER | 3 | Dec 11, 2024 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
| NCT01444820 | Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate | active not recruiting | Phase 3 | 329 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | active not recruiting | Phase 3 | 306 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03949283 | Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | active not recruiting | Phase 3 | 150 | Cordgenics, LLCINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05235516 | A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer(AK104-305) | active not recruiting | Phase 3 | 636 | AkesoINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT01584258 | Prostate Advances in Comparative Evidence(PACE) | active not recruiting | Phase 3 | 2,205 | Royal Marsden NHS Foundation TrustOTHER | 4 | Jan 19, 2024 | clinicaltrials |
| NCT03469674 | PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer(PORTEC-4a) | active not recruiting | Phase 3 | 550 | Leiden University Medical CenterOTHER | 8 | Oct 11, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT00430183 | Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | active not recruiting | Phase 3 | 788 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 9, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials